Cargando…
Surveillance arterioveNous fistulAs using ultRasound (SONAR) trial in haemodialysis patients: a study protocol for a multicentre observational study
INTRODUCTION: Arteriovenous fistulas (AVFs) are considered the best and safest modality for providing haemodialysis in patients with end-stage renal disease. Only 20% of UK centres achieve the recommended 80% target for achieving dialysis of the prevalent dialysis population via permanent access (as...
Autores principales: | Richards, James, Hossain, Mohammed, Summers, Dominic, Slater, Matthew, Bartlett, Matthew, Kosmoliaptsis, Vasilis, Wilson, Edward CF, Lagaac, Regin, Sidders, Anna, Foley, Claire, Laing, Emma, Hopkins, Valerie, Fitzpatrick-Creamer, Chloe, Hudson, Cara, Thomas, Helen, Turner, Sam, Tambyraja, Andrew, Somalanka, Subash, Hunter, James, Dutta, Sam, Lawman, Sarah, Salter, Tracey, Aslam, Mohammed, Bagul, Atul, Sivaprakasam, Rajesh, Smith, George, Moinuddin, Zia, Knight, Simon, Gibbs, Paul, Motallebzadeh, Reza, Barnett, Nicholas, Pettigrew, Gavin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661628/ https://www.ncbi.nlm.nih.gov/pubmed/31340975 http://dx.doi.org/10.1136/bmjopen-2019-031210 |
Ejemplares similares
-
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials
por: Augustin, Matthias, et al.
Publicado: (2020) -
Comment allons-nous nous en sortir?
por: Buchanan, Francine
Publicado: (2021) -
Terrell Medical Society (Regular Meeting, February 4th, Ult.)
por: Orr, James
Publicado: (1896) -
Nous autres
por: Zamiatin, Evgeniĭ Ivanovich, 1884-1937 -
Efficacy of risankizumab in patients with moderate‐to‐severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa‐1 and UltIMMa‐2 studies
por: Strober, B., et al.
Publicado: (2020)